Search by drug, manufacturer, or indication

Displaying 971 - 980 of 1165

Cortiment (budesonide)

Status:

Negotiations were not pursued

Manufacturer:

Ferring Canada Inc.

Indication:

Ulcerative Colitis

Last updated April 7, 2017

Exjade (deferasirox)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Chronic Iron Overload

Last updated April 4, 2017

Jadenu (deferasirox)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Chronic Iron Overload

Last updated April 4, 2017

Fentora (fentanyl buccal)

Status:

Negotiations were not pursued

Manufacturer:

Teva Canada Ltd.

Indication:

Pain (breakthrough), cancer (adults)

Last updated March 31, 2017

Abilify (aripiprazole)

Status:

Concluded without agreement

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Schizophrenia and Related Psychotic Disorders

Last updated March 31, 2017

Eylea (aflibercept)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Macular edema secondary to branch retinal vein occlusion

Last updated March 13, 2017

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

HIV-1 Infection

Last updated March 13, 2017

Entresto (sacubitril/valsartan)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Heart failure, NYHA class II or III

Last updated March 6, 2017

Entyvio (vedolizumab)

Status:

Concluded with an LOI

Manufacturer:

Takeda Canada Inc.

Indication:

Crohn's disease

Last updated March 3, 2017

Entyvio (vedolizumab)

Status:

Concluded with an LOI

Manufacturer:

Takeda Canada Inc.

Indication:

Ulcerative Colitis

Last updated March 3, 2017